Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-03-08
2011-03-08
Switzer, Juliet C (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07901883
ABSTRACT:
The present invention relates generally to the field of diagnostic and detection assays. More particularly, the present invention provides methods, and reagents including biochips for detecting the presence of, or distinguishing between, one or more analytes in a sample.
REFERENCES:
patent: 4983728 (1991-01-01), Herzog et al.
patent: 5346811 (1994-09-01), Galindo-Castro et al.
patent: 5364758 (1994-11-01), Meijer et al.
patent: 5411857 (1995-05-01), Beaudenon et al.
patent: 5484699 (1996-01-01), Bouma et al.
patent: 5527898 (1996-06-01), Bauer et al.
patent: 5580970 (1996-12-01), Hendricks et al.
patent: 5643715 (1997-07-01), Lancaster
patent: 5656423 (1997-08-01), Orth et al.
patent: 5705627 (1998-01-01), Manos et al.
patent: 5712092 (1998-01-01), Orth et al.
patent: 5876922 (1999-03-01), Orth et al.
patent: 5958674 (1999-09-01), Beaudenon et al.
patent: 5981171 (1999-11-01), Kuhns
patent: 5981180 (1999-11-01), Chandler et al.
patent: 6265154 (2001-07-01), Kroeger et al.
patent: 6312928 (2001-11-01), Van Gemen et al.
patent: 6352825 (2002-03-01), Meijer et al.
patent: 6482588 (2002-11-01), Van Doorn et al.
patent: 6511805 (2003-01-01), Gocke et al.
patent: 6583278 (2003-06-01), Carter
patent: 7063963 (2006-06-01), Cole et al.
patent: 7183053 (2007-02-01), Gocke et al.
patent: 2002/0081617 (2002-06-01), Buranda et al.
patent: 2003/0224385 (2003-12-01), Pihan
patent: WO 97/14028 (1997-04-01), None
patent: WO 02/24959 (2002-03-01), None
patent: WO 02/40698 (2002-05-01), None
patent: WO 03/019143 (2003-03-01), None
patent: WO 2004/018500 (2004-03-01), None
patent: WO 2005/003380 (2005-01-01), None
Baldwin et al., “Human papillomavirus infection in men attending a sexually transmitted disease clinic,” Journal of Infectious Diseases, 2003, vol. 187, pp. 1064-1070.
Bleeker et al., “Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads,” Clinical Infectious Diseases, 2005, vol. 41, pp. 612-620.
Bosch et al., “The aetiology of cervical cancer,” NHSCSP Publication No. 22, Sep. 2005, pp. 1-80.
Brown et al., “Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted disease clinic,” Sexually Transmitted Diseases, Dec. 2002, pp. 763-768.
Cavuslu et al., “Analytic sensitivities of hybrid-capture, consensus and type-specific polymerase chain reactions for the detection of human papillomavirus type 16 DNA,” Journal of Medical Virology, 1996, vol. 49, pp. 319-324.
Evans et al., “Touchdown general primer (GP5+/GP6+) PCR and optimized sample DNA concentration support the sensitive detection of human papillomavirus,” BMC Clinical Pathology, 2005, vol. 10:5, pp. 1-14.
Gravitt et al., “Improved amplification of genital human papillomaviruses,” Journal of Clinical Microbiology, Jan. 2000, vol. 38, No. 1, pp. 357-361.
Gravitt et al., “A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation,” Cancer Epidemiology, Biomarkers & Prevention, Jun. 2003, vol. 12, pp. 477-484.
Hart et al., “Novel method for detection, typing, and quantification of human papillomaviruses in clinical samples,” Journal of Clinical Microbiology, Sep. 2001, vol. 39, No. 9, pp. 3204-3212.
Jacobs et al., “A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings,” British Journal of Cancer, 1999, vol. 81(1), pp. 114-121.
Jastania et al., “Characteristics of Apparently False-Negative Digene Hybrid Capture 2 High-Risk HPV DNA Testing,” American Journal of Clinical Pathology, 2006, vol. 125(2), pp. 223-228.
Lai et al., “Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis,” International Journal of Gynecological Cancer, 2006, vol. 16, pp. 730-735.
Lapin et al., “Oncologic colpocytology collected in the public health and reference services in the diagnostic of the severity of intraepithelial cervical lesion,” Journal of Public Health, Apr. 2000, vol. 34, No. 2, pp. 120-125.
Lorincz et al., “Viral load of human papillomavirus and risk of CIN3 or cervical cancer,” The Lancet, Jul. 20, 2002, vol. 360, pp. 228-229.
McQueen et al., “Using a quality control approach to define an ‘adequately cellular’ liquid-based cervical cytology specimen,” Cytopathology, Aug. 2006, vol. 17, issue 4, pp. 168-174.
Minkoff et al., “The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women,” AIDS 2001, vol. 15, No. 16, pp. 2157-2164.
Quint et al., “Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA,” Journal of Clinical Microbiology, Feb. 2006, vol. 44, No. 2, pp. 571-579.
Ruffin et al., “Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III,” Cancer Epidemiology, Biomarkers & Prevention, Dec. 2004, vol. 13(12), pp. 2148-2152.
Sherman et al., “Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions,” Cancer Epidemiology, Biomarkers & Prevention, Oct. 2003, vol. 12, pp. 1038-1044.
Stevens et al., “Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche Amplicor and Linear Array HPV tests,” Journal of Clinical Microbiology, Jul. 2006, vol. 44, No. 7, pp. 2428-2435.
Swan et al., “A sensitive, type-specific, fluorogenic probe assay for detection of human papillomavirus DNA,” Journal of Clinical Microbiology, Apr. 1997, vol. 35, No. 4, pp. 885-891.
Swan et al., “Human papillomavirus (HPV) DNA copy number is dependant on grade of cervical disease and HPV type,” Journal of Clinical Microbiology, Apr. 1999, vol. 37, No. 4, pp. 1030-1034.
Tapsall et al., “Applications of molecular testing in clinical laboratories for the diagnosis and control of gonorrhea,” Future Microbiology, 2006, vol. 1(3), pp. 1-7.
Tsai et al., “Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk,” Cancer Epidemiology, Biomarkers & Prevention, Nov. 2005, vol. 14(11), pp. 2544-2549.
Van Duin et al., “Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance,” International Journal of Cancer, 2002, vol. 98, pp. 590-595.
Venturoli et al., “Evaluation of immunoassays for the detection and typing of PCR amplified human papillomavirus DNA,” Journal of Clinical Pathology, 1998, vol. 51, pp. 143-148.
Wallboomers et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” Journal of Pathology, 1999, vol. 189, pp. 12-19.
Weissenborn et al., “Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated,” Journal of Clinical Microbiology, Jun. 2003, vol. 41, No. 6, pp. 2763-2767.
Ylitalo et al., “Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study,” The Lancet, Jun. 24, 2000, vol. 355, pp. 2194-2198.
Zerbini et al., “Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA,” Journal of Clinical Pathology, 2001, vol. 54, pp. 377-380.
Defoort, J-P et al. 2000 “Simultaneous detection of multiplex-amplified Human Immunodeficiency Virus Type 1 RNA, Hepatitis C Virus RN
Gould Toby
Poetter Karl
Genera Biosystems Limited
Knobbe Martens Olson & Bear LLP
Switzer Juliet C
LandOfFree
Human papilloma virus (HPV) detection using nucleic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human papilloma virus (HPV) detection using nucleic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human papilloma virus (HPV) detection using nucleic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2700687